What is ulotaront? An Introduction to a Novel Investigational Drug
•
4 min read
In 2019, ulotaront received Breakthrough Therapy Designation from the FDA for schizophrenia, based on promising Phase 2 trial results. This investigational drug, ulotaront, is a first-in-class trace amine-associated receptor 1 (TAAR1) agonist representing a new approach to treating psychiatric conditions with a distinct safety profile.
